New stent aims to keep leg arteries open longer
NCT ID NCT06410313
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early study tests a new stent coated with a drug called ridaforolimus in 30 people with blocked arteries in the thigh or knee area. The stent is designed to prop the artery open and slowly release medication to prevent it from narrowing again. Participants will be followed for three years to see if the artery stays open and if the treatment is safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ridaforolimus (drug-coated stent)
What this could lead to
If successful, this stent could offer a new option to keep leg arteries open longer, reducing the need for repeat procedures.
What could go wrong
This is a very early, small study (30 people) with no comparison group. The stent may not work as hoped, and risks include reblockage or complications from the procedure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SUPERFICIAL FEMORAL ARTERY STENOSIS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Columbia University Medical Center/ NewYork Presbyterian Hospital or CUMC/NYPH
NOT_YET_RECRUITINGNew York, New York, 10032, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Piedmont Healthcare, Inc.
NOT_YET_RECRUITINGAtlanta, Georgia, 30318, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Royal North Shore Hospital
RECRUITINGSydney, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Royal Perth Hospital
NOT_YET_RECRUITINGPerth, Australia
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Royal Prince Alfred Hospital
RECRUITINGSydney, Australia
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
St Francis Hospital Heart Center
NOT_YET_RECRUITINGRoslyn, New York, 11576, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The Alfred Hospital
RECRUITINGMelbourne, Australia
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••